2024-10-27 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report

**1. Performance Comparison:**

Vertex Pharmaceuticals Inc (VRTX) has outperformed the S&P 500 (VOO) by **38.48%** since the start of the period being analyzed. This performance places it in the **73.42nd percentile** relative to the historical performance range of VRTX against VOO.

**Company Overview:** 

Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for serious and life-threatening diseases, particularly cystic fibrosis.

**2. Recent Price Movement:**

* **Closing Price:** $471.91 (Last Market: $477.69)
* **5-day Moving Average:** $475.59
* **20-day Moving Average:** $471.76
* **60-day Moving Average:** $475.19

The current price is slightly below the 5-day and 60-day moving averages, suggesting recent price volatility.

**3. Technical Indicators:**

* **RSI:** 59.39 - Suggests the stock is in neutral territory, neither overbought nor oversold.
* **PPO:** 0.01 - Indicates a slight bullish momentum.
* **Delta_Previous_Relative_Divergence:** 1.76 (+) - Shows a recent short-term uptrend.
* **Expected Return:** 5.86% -  This suggests a potential for long-term (2+ years) outperformance compared to the S&P 500 through a buy-and-hold strategy.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

* **Most Recent Earnings:** The latest earnings report on 2024-08-02 showed an EPS of -13.92, significantly lower than expectations. While revenue of 2.65B$ was in line with expectations, the EPS miss raises concerns about the company's near-term performance. 

**5. News and Recent Issues:**

* **Recent Earnings News:** The recent earnings report on August 2nd caused a significant drop in the stock price, suggesting investor concerns about the company's profitability. 
* **Recent Market Outlook:** FINBOLD analysts remain positive about Vertex Pharmaceuticals long-term prospects, citing its dominant position in the cystic fibrosis market and a promising pipeline of new treatments. However, analysts acknowledge the recent EPS miss and are waiting for further clarification on the company's strategy and outlook.
* **Analyst Opinions and Performance Highlights:**  A majority of analysts currently rate VRTX as a "Buy" or "Strong Buy," with a consensus price target of $500. However, recent price performance and the latest earnings report have prompted some analysts to revise their outlooks.

**6. Comprehensive Analysis:**

Vertex Pharmaceuticals Inc (VRTX) has historically outperformed the S&P 500. However, recent earnings missed expectations, leading to a significant drop in the stock price. Despite this, technical indicators suggest a slight bullish momentum in the short term, and long-term prospects remain positive based on the company's leading position in the cystic fibrosis market and its pipeline of new treatments. 

**7. Recommendations:**

Investors should carefully consider the recent earnings miss and the company's future outlook before making investment decisions. However, the long-term potential for VRTX remains promising, making it a potential candidate for investors seeking growth opportunities within the healthcare sector. It is recommended to monitor future earnings reports and analyst opinions closely for further insight into the company's trajectory.

**Disclaimer:** This report is for informational purposes only and should not be considered as investment advice. Please conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
